About this trial
This trial is for people with oligometastatic breast cancer (OMBC), which means their breast cancer has spread from the breast to a maximum of five places in the body. The cancer can have spread to between 1 and 5 spots, and to no more than two different organs (for example the lungs, liver, or bones).
This is a large, late-stage (phase III) clinical trial being carried out in multiple hospitals across Europe. It’s designed to find out whether adding a special type of high-dose, targeted radiation treatment known as stereotactic ablative radiation therapy (SABR) to standard first-line treatment (such as hormonal therapy, targeted therapy or chemotherapy) can improve outcomes for people with OMBC.
Who can take part?
This study is for men and women over the age of 18 who have a confirmed diagnosis of recurrent or de novo OMBC.
OMBC
- Recurrent means the cancer has returned after previous treatment.
- De novo means the cancer was already metastatic (had spread) at the time of the initial diagnosis.
OMBC is defined, for this study, as having 1 to 5 areas of cancer spread (metastases) in no more than two organs (for example the lungs, liver, or bones).
Patients already receiving first-line systemic treatment can join the trial if repeated tumour evaluations (such as a CT scan) show that the disease is stable.
The St Luke’s Radiation Oncology Network: St. Luke’s Centre @ Beaumont Hospital:
IMAGE
For more in-depth or technical details (primarily for healthcare professionals, but open to all):